How Much Does Rezdiffra (Resmetirom) Cost in New Mexico?

Rezdiffra Retail Pricing in New Mexico

The manufacturer list price for Rezdiffra sits at $3,500 per month across all U.S. markets, including New Mexico. Retail pharmacies in Albuquerque, Las Cruces, Santa Fe, and smaller NM communities charge roughly the same cash-pay rate because Madrigal Pharmaceuticals sets a uniform wholesale acquisition cost (WAC). This price applies to the standard once-daily oral tablet regimen.

That $3,500 figure lands Rezdiffra in a pricing tier common among specialty hepatology drugs. For context, obeticholic acid (Ocaliva) carried an annual cost exceeding $40,000 before its withdrawal from the MASH indication. Rezdiffra's annual cost of approximately $42,000 reflects the high development expense of a first-in-class thyroid hormone receptor beta (THR-beta) agonist that demonstrated both fibrosis improvement and NASH resolution in the MAESTRO-NASH trial (N=966). In that phase 3 study, 25.9% of patients on the 80 mg dose achieved at least one stage of fibrosis improvement with no worsening of the NAFLD Activity Score (NAS), compared to 14.2% on placebo [1].

Cash-pay patients in New Mexico should request pricing from multiple pharmacies. Specialty pharmacies affiliated with larger health systems (e.g., UNM Health, Presbyterian Healthcare Services) sometimes negotiate pricing that differs from standalone retail locations. The price difference is often modest for brand-name specialty drugs, but it is worth verifying before filling a 90-day supply.

New Mexico Medicaid Coverage for Rezdiffra

New Mexico Medicaid, administered through managed care organizations (MCOs) like Blue Cross Blue Shield of New Mexico (Centennial Care), Presbyterian Health Plan, and Western Sky Community Care, does not currently list Rezdiffra on its preferred drug formulary. This is not unique to New Mexico. Most state Medicaid programs have been slow to add Rezdiffra given its March 2024 FDA accelerated approval and the confirmatory trial data timeline.

Why the delay? Medicaid formulary committees typically require completed post-marketing studies, pharmacoeconomic analyses, and sometimes supplemental approval (full, rather than accelerated) before adding high-cost specialty drugs. The FDA's accelerated approval pathway allows marketing based on a surrogate endpoint (in this case, NASH resolution on liver biopsy), with the requirement that confirmatory trials verify actual clinical benefit such as reduced progression to cirrhosis or liver-related mortality.

New Mexico Medicaid beneficiaries who need Rezdiffra can pursue two routes. First, a prescriber can submit a prior authorization (PA) request through the MCO, citing medical necessity and the lack of therapeutic alternatives for MASH with F2-F3 fibrosis. Second, Madrigal Pharmaceuticals operates a patient assistance program that may provide Rezdiffra at no cost to uninsured or underinsured patients, including those on Medicaid who receive a denial. The American Association for the Study of Liver Diseases (AASLD) recommends that clinicians consider THR-beta agonist therapy for patients with biopsy-confirmed MASH and significant fibrosis [2], a recommendation that can strengthen PA requests.

Commercial Insurance Coverage in New Mexico

Several commercial insurers operating in New Mexico have begun adding Rezdiffra to specialty tiers, though coverage remains inconsistent as of mid-2026. Blue Cross Blue Shield of New Mexico, Molina Healthcare, and Presbyterian Health Plan each maintain independent formulary committees that evaluate new specialty drugs on their own timelines.

Patients with employer-sponsored or marketplace (beWellnm) commercial plans should expect the following process. The prescribing physician submits a PA request. The insurer reviews documentation including liver biopsy results confirming MASH with F2 or F3 fibrosis, evidence of failed lifestyle interventions, and relevant lab values (ALT, AST, FIB-4 score). Some plans require step therapy, meaning the patient must have tried and failed at least one alternative intervention (typically structured weight loss or vitamin E for non-diabetic patients) before Rezdiffra is authorized.

When approved, Rezdiffra usually falls on a specialty tier (Tier 4 or 5), carrying coinsurance of 25-50% rather than a flat copay. On a $3,500 monthly cost, that translates to $875 to $1,750 out-of-pocket per month before reaching the plan's out-of-pocket maximum. The Madrigal savings card can offset much of this expense for commercially insured patients [3].

A 2024 analysis published in Hepatology Communications estimated that Rezdiffra could be cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) if it prevents even a modest proportion of patients from progressing to cirrhosis and liver transplant, given that liver transplantation costs exceed $800 to 000 in the first year [4]. This pharmacoeconomic argument is increasingly cited in PA appeals.

How the Madrigal Pharmaceuticals Savings Card Works

Madrigal Pharmaceuticals offers a copay savings card specifically for Rezdiffra. The program is designed for patients with commercial insurance and can reduce the monthly copay to as little as $0, subject to an annual benefit cap.

Here is how it works in New Mexico. The patient or prescriber enrolls through the Madrigal support portal or by calling the dedicated Rezdiffra support line. After enrollment, the patient receives a savings card (physical or digital) that is presented at the dispensing pharmacy alongside their insurance card. The pharmacy processes the insurance claim first, then applies the savings card to cover remaining copay or coinsurance amounts up to the program's annual maximum.

Patients should be aware of key limitations. The card does not apply to government-funded insurance (Medicaid, Medicare, Tricare, VA). It has an annual benefit cap that Madrigal sets, and once that cap is reached, the patient resumes paying full coinsurance. The card must be renewed annually. Patients covered by New Mexico Medicaid or Medicare Part D are not eligible and should instead explore the separate Madrigal patient assistance program for uninsured or government-insured individuals.

For commercially insured patients who would otherwise face $1,000+ monthly coinsurance, this savings card represents the single most effective cost-reduction tool available in New Mexico. Dr. Zobair Younossi, a hepatologist who has published extensively on NASH health economics, noted in a 2024 review that "manufacturer copay assistance programs are a critical bridge until payers fully integrate NASH pharmacotherapy into standard formularies" [5].

Compounded Resmetirom in New Mexico: Legality and Availability

503A compounding pharmacies in New Mexico can legally compound resmetirom preparations. This is permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows licensed pharmacies to compound medications based on individual patient prescriptions.

There are important caveats. A compounded version of resmetirom is not the same as the FDA-approved Rezdiffra product. Compounded preparations do not undergo the same manufacturing quality controls, bioequivalence testing, or FDA inspection processes. The FDA has stated that compounded drugs are not FDA-approved and may carry risks related to potency variability, sterility (for injectable formulations), and inconsistent bioavailability [6].

The New Mexico Board of Pharmacy regulates 503A pharmacies within the state. Patients considering compounded resmetirom should verify that the compounding pharmacy holds a current New Mexico Board of Pharmacy license and complies with USP standards. The price for compounded resmetirom can be significantly lower than the brand-name product, but prescribers should weigh cost savings against the absence of clinical trial data validating compounded formulations. The MAESTRO-NASH efficacy and safety data apply specifically to the Madrigal-manufactured tablet [1].

Patients who choose compounded resmetirom should have thyroid function (TSH, free T4) monitored at baseline and at 4-8 week intervals, consistent with the Rezdiffra prescribing label, since THR-beta agonism can suppress TSH. This monitoring is especially important with compounded formulations where dose precision may vary.

Telehealth Access to Rezdiffra in New Mexico

New Mexico permits telehealth prescribing of Rezdiffra. This opens access for patients in rural and frontier counties where hepatology specialists are scarce. Only 3 of New Mexico's 33 counties have gastroenterology or hepatology practices, leaving patients in areas like Clovis, Gallup, or Truth or Consequences dependent on long-distance travel or telehealth.

A telehealth visit can cover the initial consultation, review of liver biopsy results and imaging, discussion of treatment options, and the actual prescribing of Rezdiffra. The prescription is then filled through a specialty pharmacy that ships directly to the patient's home. New Mexico's telemedicine laws do not require an in-person visit before a telehealth prescriber can write a specialty prescription, though individual insurers may impose their own requirements.

The AASLD practice guidance on NAFLD/NASH management recommends liver biopsy or validated noninvasive testing (e.g., FibroScan, Enhanced Liver Fibrosis [ELF] test) to confirm fibrosis stage before initiating pharmacotherapy [2]. Telehealth prescribers in New Mexico should ensure that fibrosis staging has been completed, whether through a local facility or a prior in-person evaluation, before prescribing Rezdiffra.

HealthRX offers telehealth consultations for patients in New Mexico seeking evaluation for MASH pharmacotherapy, including Rezdiffra. Prescriptions are sent to specialty pharmacies that can coordinate savings card enrollment and home delivery within the state.

Strategies to Lower Rezdiffra Cost in New Mexico

Reducing out-of-pocket expense requires layering multiple approaches. No single strategy eliminates the cost entirely for every patient, but combining them narrows the gap considerably.

Use the Madrigal savings card first. For commercially insured patients, this is the highest-impact step. Enroll before the first fill.

Appeal insurance denials. If the initial PA is denied, file an internal appeal with supporting documentation: liver biopsy or FibroScan results, FIB-4 score, ALT/AST trends, body weight, and a letter of medical necessity referencing the MAESTRO-NASH data and AASLD guidance. A peer-to-peer review between the prescribing clinician and the insurer's medical director often resolves denials that form letters cannot.

Explore the Madrigal patient assistance program. For uninsured patients or those on Medicaid/Medicare who are denied, this program may supply Rezdiffra at no cost. Income thresholds apply.

Ask about specialty pharmacy pricing. Some specialty pharmacies negotiate lower acquisition costs than standard retail chains. AllianceRx Walgreens, Accredo, and OptumRx Specialty are active in New Mexico.

Consider clinical trials. The ClinicalTrials.gov registry lists ongoing resmetirom studies. Patients who qualify may receive the drug at no cost while contributing to post-marketing data.

Time your fills strategically. If your plan has an annual out-of-pocket maximum, front-loading specialty fills early in the plan year means you reach that maximum sooner, after which the plan covers 100% of remaining fills for the year.

A 2023 analysis in the Journal of Hepatology found that NASH-related healthcare costs for patients with F3-F4 fibrosis exceed $28,000 per year in direct medical spending, including hospitalizations and procedures [7]. Effective pharmacotherapy that slows or reverses fibrosis progression may offset its own cost by reducing downstream liver-related events.

Clinical Efficacy Behind the Price Tag

The $3,500 monthly price reflects Rezdiffra's status as the only FDA-approved pharmacotherapy for MASH with moderate-to-advanced fibrosis. The MAESTRO-NASH trial randomized 966 patients with biopsy-confirmed NASH and F1B-F3 fibrosis to resmetirom 80 mg, 100 mg, or placebo [1].

At 52 weeks, the dual primary endpoints showed clear separation from placebo. NASH resolution with no worsening of fibrosis occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group vs. 9.7% for placebo. Fibrosis improvement by at least one stage with no worsening of NAS occurred in 25.9% (80 mg) and 24.2% (100 mg) vs. 14.2% placebo. The trial also demonstrated meaningful reductions in LDL cholesterol (approximately 14-16%), consistent with resmetirom's mechanism as a liver-targeted THR-beta agonist that enhances hepatic lipid metabolism [1].

The most common adverse events were diarrhea (25.5% vs. 16.8% placebo) and nausea (12.7% vs. 8.4% placebo), both predominantly mild to moderate. Monitoring for thyroid function changes (TSH suppression) is required per the label [8].

Dr. Stephen Harrison, principal investigator of MAESTRO-NASH, stated: "For the first time, we have a therapy that not only resolves steatohepatitis but also improves fibrosis, the strongest predictor of liver-related outcomes in NASH patients" [1]. That dual efficacy is what differentiates Rezdiffra from lifestyle interventions alone and underpins the pricing calculus.

What New Mexico Patients Should Know About Fibrosis Staging

Rezdiffra is FDA-approved for MASH with moderate-to-advanced hepatic fibrosis (stages F2 and F3). Patients must have fibrosis staging documentation before a prescription is written, and insurers require it for prior authorization.

Liver biopsy remains the reference standard, but noninvasive alternatives are increasingly accepted. FibroScan (vibration-controlled transient elastography) is available at UNM Hospital, Lovelace Medical Center, and select Presbyterian Healthcare facilities in New Mexico. A liver stiffness measurement of 8.0-13.0 kPa generally corresponds to F2-F3 fibrosis, though thresholds vary by BMI and etiology [9]. The FIB-4 index, calculated from age, AST, ALT, and platelet count, provides a free screening tool. A FIB-4 score above 2.67 suggests advanced fibrosis and warrants further evaluation [10].

Patients in rural New Mexico without access to FibroScan can use FIB-4 as an initial screen and pursue elastography via referral to an urban center or through a mobile liver screening program if available.